Design and Implementation of Intelligent Operation Informatization of Medical Consumables Based on Operational Data Repository / 医学信息学杂志

Purpose/Significance In order to coordinate and promote the high-quality development of hospitals,medical consuma-bles refined supply processing distribution(SPD)based on operational data repository(ODR)is built.Through ODR,cross-depart-mental data collaboration is realized,and an intelligent operation management system for medical consumables is established.Method/Process Through informatization design and application scenario analysis,the intelligent operation management architecture and service mode of consumables are constructed with data governance as the starting point.Result/Conclusion The intelligent operation system of medical consumables based on ODR will consolidate the fine management results under the SPD mode,strengthen hospital risk control,and further improve the scientific and standardized level of hospital operation and management.

Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials / 中华医学杂志(英文版)

<p><b>BACKGROUND</b>Ertapenem has been demonstrated to be highly effective for the treatment of complicated infections. The aim of this study was to compare the efficacy and safety of ertapenem with ceftriaxone.</p><p><b>METHODS</b>We searched the PubMed, EMBASE, and the Cochrane Library for published randomized controlled trials (RCTs) that compared the efficacy and safety of ertapenem with ceftriaxone for the treatment of complicated infections including community-acquired pneumonia (CAP), complicated urinary tract infections (cUTIs), and complicated intra-abdominal infections (cIAIs). Meta-analysis was performed by RevMan 5.0.</p><p><b>RESULTS</b>Eight RCTs, involving 2 883 patients, were included in our meta-analysis. Ertapenem was associated with similar clinical treatment success with ceftriaxone for complicated infections (1 326 patients, fixed-effect model, OR: 1.13, 95% CI: 0.75-1.71). There was no difference between the compared treatment groups with regard to the microbiological treatment success, and no difference was found with regard to the incidence of clinical and laboratory drug-related adverse events between ertapenem and ceftriaxone groups. As to local tolerability, overall, there was no difference between the compared groups; however, in the subgroup analysis, local reaction was significantly less in the ertapenem subgroup than the ceftriaxone plus ceftriaxone subgroup.</p><p><b>CONCLUSIONS</b>Ertapenem can be used as effectively and safely as ceftriaxone for the treatment of complicated infections. It is an appealing option for the treatment of these complicated infections.</p>